WSGR logoWSGR logo
Joseph E. Lesniewski
Associate
Patents and Innovations
Washington, D.C.

D202-920-8734

Download vCard
Open PDF

Dr. Joseph E. Lesniewski (Joe) is an associate in the Washington, D.C., office of Wilson Sonsini Goodrich & Rosati, where he is a member of the patents and innovations practice. He has extensive interdisciplinary technical expertise that spans across the fields of physical chemistry, organic chemistry, inorganic chemistry, analytical chemistry, computer science, and mechanical and electrical engineering.

Joe earned his Ph.D. in chemistry from Georgetown University, where his doctoral research focused on designing new ion sources and chemical instrumentation for efficient detection and quantitation of nonmetal elements by elemental mass spectrometry. His research was applied towards pharmaceutical development and trace analysis of contaminants in complex sample matrices.

Joe has also conducted research at the National Institute of Standards and Technology (NIST), where he focused on development of an automation software package for refinement of magnetic and nonmagnetic crystal structures from neutron and x-ray diffraction patterns using high-performance computing clusters.

Prior to joining the firm, Joe was an intellectual property and commercialization intern at Georgetown University’s Office of Technology Commercialization, where he gained experience marketing technologies to potential licensees and working with patent applications from a variety of fields including small molecules, medical devices, energy technologies, and computer science technologies.

Joe is an inventor on U.S. Patent No. 12,322,584.

Experience

Dr. Joseph E. Lesniewski (Joe) is an associate in the Washington, D.C., office of Wilson Sonsini Goodrich & Rosati, where he is a member of the patents and innovations practice. He has extensive interdisciplinary technical expertise that spans across the fields of physical chemistry, organic chemistry, inorganic chemistry, analytical chemistry, computer science, and mechanical and electrical engineering.

Joe earned his Ph.D. in chemistry from Georgetown University, where his doctoral research focused on designing new ion sources and chemical instrumentation for efficient detection and quantitation of nonmetal elements by elemental mass spectrometry. His research was applied towards pharmaceutical development and trace analysis of contaminants in complex sample matrices.

Joe has also conducted research at the National Institute of Standards and Technology (NIST), where he focused on development of an automation software package for refinement of magnetic and nonmagnetic crystal structures from neutron and x-ray diffraction patterns using high-performance computing clusters.

Prior to joining the firm, Joe was an intellectual property and commercialization intern at Georgetown University’s Office of Technology Commercialization, where he gained experience marketing technologies to potential licensees and working with patent applications from a variety of fields including small molecules, medical devices, energy technologies, and computer science technologies.

Joe is an inventor on U.S. Patent No. 12,322,584.

Focus Areas
Recent Insights
Client Highlights
Firm Advises Matterworks on IP and Patent Matters Related to Series A Financing
On June 3, 2025, Matterworks, Inc., the category-defining pioneer unlocking unstructured molecular data for predictive biology, announced a new Series A financing. The round was led by Lewis & Clark Partners and OMX Ventures and joined by Pillar VC, Germin8 Ventures, Intermountain Ventures, and Tarsadia, among others. Matterworks will use the Series A proceeds to grow its model as a service (MaaS) business and expand its machine learning and scientific operations. For example, Matterworks' Large Spectral Models (LSMs) productize self-supervised machine intelligence for direct machine interpretation of molecular-omic data. The company’s PyxisTMproduct, released in 2024, is the first generative AI for complete untargeted molecular annotation, unlocking new data modalities for understanding and predicting complex biological outcomes.
Learn More
Client Highlights
Wilson Sonsini Advises on Patent Matters Related to Verona’s FDA Approval
On June 26, 2024, Verona Pharma announced that the U.S. Food and Drug Administration approved Ohtuvayre (ensifentrine) for the maintenance treatment of chronic obstructive pulmonary disease (COPD) in adult patients. Ohtuvayre is the first inhaled product with a novel mechanism of action available for the maintenance treatment of COPD in more than 20 years. Wilson Sonsini Goodrich & Rosati advised Verona Pharma on patent matters.
Learn More
View All
WSGR logo
Copyright © 2026 Wilson Sonsini Goodrich & Rosati. All Rights Reserved.